Wan X S, Hamilton T C, Ware J H, Donahue J J, Kennedy A R
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Nutr Cancer. 1998;31(1):8-17. doi: 10.1080/01635589809514672.
Bowman-Birk inhibitor (BBI) is a soybean-derived anticarcinogenic protease inhibitor that was shown to potentiate the cytotoxicity of cisplatin in our previous studies. To assess the potential of BBI as a sensitizing agent for the chemotherapy of cisplatin-resistant cancers, we evaluated the effects of a soybean concentrate enriched in BBI (known as BBI concentrate or BBIC) on cell growth and clonogenic survival of a human ovarian cancer cell line, A2780, and its cisplatin-resistant sublines, C30, and C200. The presence of BBI and BBIC in the cell culture, medium reduced the clonogenic survival of the A2780, C30, and C200 cells in a dose-dependent manner and enhanced cisplatin-induced growth inhibition and/or cytotoxicity. BBIC alone showed greater inhibitory effects on growth in the cisplatin-resistant cell lines. These results suggest that BBI and BBIC could be useful agents for the treatment of cancers, especially with cisplatin, in tumors resistant to this important anticancer agent.
鲍曼-伯克抑制剂（BBI）是一种源自大豆的抗癌蛋白酶抑制剂，在我们之前的研究中显示它能增强顺铂的细胞毒性。为了评估BBI作为顺铂耐药癌症化疗增敏剂的潜力，我们评估了富含BBI的大豆浓缩物（称为BBI浓缩物或BBIC）对人卵巢癌细胞系A2780及其顺铂耐药亚系C30和C200细胞生长和克隆形成存活的影响。细胞培养物和培养基中BBI和BBIC的存在以剂量依赖的方式降低了A2780、C30和C200细胞的克隆形成存活，并增强了顺铂诱导的生长抑制和/或细胞毒性。单独使用BBIC对顺铂耐药细胞系的生长显示出更大的抑制作用。这些结果表明，BBI和BBIC可能是治疗癌症的有用药物，特别是与顺铂联合用于对这种重要抗癌药物耐药的肿瘤。
